OncoImmunity has recently teamed up with the Tumor Neoantigen Selection Alliance (TESLA). This initiative is an international consortium founded by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (CRI). This global bioinformatics collaboration includes world-leading scientists from more than 35 of the leading neoantigen research groups in academia, biotech and big-pharma. By participating in this consortium OncoImmunity will have the opportunity to further validate its artificial intelligence platform to predict truly immunogenic neoantigens that can be used for personalized cancer immunotherapy.
